David Ricks

David Ricks became CEO of Eli Lilly in January 2017 and has overseen the most spectacular value creation in pharmaceutical industry history. Under his leadership, Lilly's market capitalization has grown from approximately $80 billion to over $800 billion, making it the world's most valuable pharmaceutical company — surpassing longtime leaders like Johnson & Johnson, Roche, and Pfizer. The driver is the GLP-1 receptor agonist revolution. Lilly's tirzepatide molecule, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, represents a once-in-a-generation therapeutic breakthrough. GLP-1 drugs don't just lower blood sugar — they produce dramatic weight loss of 15-25% of body weight, with emerging data showing cardiovascular, kidney, and liver benefits. The addressable market is potentially hundreds of millions of patients worldwide. Ricks made the strategic bet on GLP-1 early, investing heavily in manufacturing capacity when competitors hesitated. Lilly has committed over $20 billion in manufacturing expansion to meet demand that continues to exceed supply. This manufacturing buildout represents both Lilly's competitive moat and its biggest execution risk. Beyond GLP-1, Ricks has built a formidable pipeline including donanemab (Alzheimer's), mirikizumab (Crohn's disease), and next-generation diabetes therapies. He has navigated the political controversy around drug pricing, with GLP-1 drugs facing scrutiny over their $1,000+/month list prices. The key question for investors is whether Lilly can maintain its manufacturing and competitive lead as Novo Nordisk's Ozempic/Wegovy and new entrants challenge for market share in what may become the largest drug category in history.